Shareholders Equity: The sum of preferred and common equity items.
Telix Pharmaceuticals Limited (TLX) had Shareholders Equity of $415.38M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$330.28M |
|
$64.41M |
|
$782.51M |
|
$1.16B |
|
$231.62M |
|
$448.45M |
|
$516.99M |
|
$748.61M |
|
$415.38M |
|
$-177.45M |
|
|
Shareholders Equity |
$415.38M |
-- |
|
| Cash Flow Statement Financials | |
$-17.29M |
|
$-285.92M |
|
$-3.72M |
|
$440.00M |
|
$141.87M |
|
$-298.13M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|